Skip to content

9 results for "Meta-analysis: What did research on Cannabis find in April 2026?"

Pharmacokinetic study of delta-8-tetrahydrocannabinol in male rats using a validated bioanalytical method.

Journal of Analytical Toxicology April 30, 2026 Alexandria S. Senetra, Sushobhan Mukhopadhyay, Yi-Hua Chiang et al.

Delta-8-tetrahydrocannabinol (Δ8THC) has been growing in popularity across the United States due to its reported therapeutic benefits, including pain relief, euphoria, relaxation, and mild psychoactive effects, especially in areas where sale of delta-9-tetrahydrocannabinol (Δ9THC) is illegal. Currently, much debate surrounds Δ8THC regarding its regulatory status and whether this compound is...

A Systematic Review of Clinical Phenomenology, Differential Diagnosis and Prognostic Outcomes of Substance-Induced Psychotic Disorders.

The International journal of social psychiatry April 26, 2026 Valerio Ricci, Giovanni Martinotti, Giuseppe Maina

Distinguishing substance-induced psychotic disorders (SIPD) from primary psychotic disorders with concurrent substance use remains a critical diagnostic challenge for treatment planning and prognostic counseling. To systematically review the clinical phenomenology of SIPD, identify distinguishing symptom patterns, and examine relationships between phenomenology and outcomes. A systematic search...

Regular cannabis use is associated with altered neural and behavioural responses during anticipation and feedback of monetary reward and loss

medRxiv Preprint Server April 23, 2026 Giada Lombardi, Grace Blest‐hopley, Martina Maria Tarantini et al. preprint

Regular cannabis use has been associated with alterations in reward-related neural processes, yet findings remain inconsistent and the relationship between neural activity and behavioural performance is not fully understood. The present study aimed to characterise neural and behavioural correlates of reward processing in regular cannabis users (CU) compared with matched non-users (NU) using the...

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

Cancer causes & control : CCC April 22, 2026 Amrit Baral, Yue Pan, Wayway M. Hlaing et al.

To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...

Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.

The American journal of psychiatry April 17, 2026 Shih-Hsuan Ku, Sierra J Stringfield, Mary M Torregrossa et al.

The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant interest within psychiatry. Cannabis is the most widely used recreational drug worldwide, and individuals with schizophrenia use it at a much higher rate than the general population. The shared genetic risk for schizophrenia and cannabis...

Cannabis use by people with HIV is associated with an anti-inflammatory immunometabolic phenotype in monocyte-derived macrophages.

Journal of Neuroinflammation April 17, 2026 Mary K Ford, Peter W Halcrow, Anna E Laird et al.

Chronic neuroinflammation is associated with comorbidities in people with HIV (PWH) on antiretroviral therapy (ART). While cannabis use is associated with reduced neuroinflammation and neurocognitive impairment (NCI) in PWH, the underlying mechanisms are unknown. To address this gap in knowledge, we analyzed monocyte-derived macrophages (MDMs) from a cohort of 50 PWH and 33 people without HIV...

Marcus Clarke’s “Cannabis Indica” and Altered States of Consciousness in 19th-Century Australian Mass Media

Journal of Australian studies April 3, 2026 Clare J. Burnett

ABSTRACT In 1868 eminent Australian author Marcus Clarke wrote a gothic tale for his own Colonial Monthly Magazine titled “Cannabis Indica”, purportedly under the influence of hashish. Contemporaneous reviewers discussed this little-known short story as merely a curio, and modern scholars have followed suit. However, the experimental short story is distinguished as one of the first fictional...

The Sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of the cannabinoid receptor agonist delta9-tetrahydrocannabinol in rats and mice.

Pharmacological reports : PR April 1, 2026 Elmira Zolali, Mallory Burns, Sebastiano Intagliata et al.

BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...

Perceptions of Delta-8 THC and the Impact of a Brief Educational Video Intervention for College Students.

The journal of behavioral health services & research April 1, 2026 Destin Rothe, Erica K Yuen, Kathleen A Moore et al.

Delta-8 THC is a psychoactive cannabinoid typically synthesized from hemp, with similar intoxicating effects as delta-9 THC. Surging public interest alongside the lack of federal regulation of delta-8 THC has led to an unclear legal landscape and increasing safety concerns. Educating young adults about the dangers of delta-8 THC is imperative. The current study investigated the effects of a...